Effect of DAPAglifozin on MYOcardial Remodeling of Breast CANCER Patients Treated with Anthracycline Based Chemotherapy
Recruiting · NCT06711185 · Interventional (participants receive a specific treatment) · Lead sponsor: University of Campinas, Brazil
View the official record on ClinicalTrials.gov →Interventions studied
Dapagliflozin 10 mgPlacebo
What this trial is about
Prospective, randomized, double-blind, controlled clinical trial to compare the effect of 9 months of treatment with dapagliflozin vs. placebo on anthracycline-induced cardiotoxicity in patients with breast cancer.
Who can take part
Age range
18 Years and older
Sex
Female
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 3
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Female
- Over 18 years old
- Breast cancer
- Chemotherapy as treatment planning and programmed cumulative dose equivalent to 240 mg/m2 of doxorubicin.
Exclusion criteria
- Contraindications for performing CMR exams, such as patients with pacemakers or cardiac defibrillators of any type, metal clips for cerebral aneurysms, cochlear implants, and ventriculoperitoneal bypass valves.
- Inability to perform CMR due to claustrophobia.
- Renal failure with a glomerular filtration rate \< 30 ml/min/1.73 m2.
- Previous history of myocardial infarction, congestive heart failure, or myocardial revascularization, whether percutaneous or surgical.
- Previous history of significant valvular heart disease.
- Previous history of cardiomyopathies.
Where it is running
1 location listed.
- Hospital de Clinicas da Unicamp - Campinas, São Paulo, Brazil